NDAORAL-28TABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
NORLESTRIN 28 1/50 (ethinyl estradiol; norethindrone acetate) by Pfizer. Approved for pregnancy.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLESTRIN 28 1/50 is an oral combined hormonal contraceptive containing ethinyl estradiol and norethindrone acetate in a 28-day tablet formulation. It is indicated for pregnancy prevention through estrogen-progestin mechanism. This product is currently in pre-launch phase under Pfizer sponsorship.
Pre-Launch
Pre-launch status indicates active team building for regulatory, commercial, and medical affairs roles with focus on market entry strategy and competitor positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on NORLESTRIN 28 1/50 offers career opportunity in a product launch phase within Pfizer's established women's health portfolio, though zero current linked job postings suggest hiring has not yet scaled. This pre-launch role typically involves cross-functional collaboration on market positioning, regulatory submissions, and competitive intelligence against entrenched oral contraceptive and alternative delivery system competitors.
Worked on NORLESTRIN 28 1/50 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.